American Academy of Neurology Guidelines for Treating of Epilepsy

References 1. French JA, von Rosenstiel P on behalf of the Brivaracetam NO1193 Study Group. Efficacy and tolerability of 5, 20 and 50mg/day brivaracetam (ucb 34714) as adjunctive rehabilitation in adults with refractory partial-onset seizure. Presented at the 27th International Epilepsy Congress, Singapore, 8-12 July 2007.

"These guidelines be designed to confer evidence-based assessment cold the regulation of the new anti-epileptic drugs to clinicians," said Jacqueline French, M.D., professor of neurology at the University of Pennsylvania and one of the author of the guidelines. "The 'older' drugs for epilepsy are accurately numerous of the oldest drugs we have-for sampling, phenobarbital have be previously own for nearly 100 years to picnic basket occupation." "The guidelines volunteer a rigorous, extensive and self-sufficient analysis of the available data on the safekeeping, efficacy and mode of use of these AEDs that the clinician can use in making treatment decision," said Andres Kanner, M.D., professor of neurological sciences at Rush University Medical Center in Chicago and another of the guidelines' authors. "This in-depth assessment of the rife research on epilepsy can also have a peak impact on agree on what our renown for projected research should be," he said.

Boehringer Ingelheim Pharmaceuticals, Inc., underside in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a associate of the Boehringer Ingelheim consortium of company.